John Mildenberger is identified in the byline as the specialty pharmacy manager, senior clinical lead pharmacist, and community pharmacy compliance officer at Sidney Regional Medical Center in Sidney, Nebraska. He reports having established a specialty pharmacy in that small town and describes the rural context in which he practices.
The article frames the author’s perspective as rooted in direct experience running a community specialty pharmacy and interacting with patients who travel long distances to obtain specialty therapies.
Mildenberger emphasizes that patients drive “miles and hours” across rural Nebraska to reach his pharmacy. He contrasts the local, in-person service he provides with remote, mail-order distribution models. According to the author, patients are often pleased to pick up medications such as Rinvoq at his counter and to speak with a clinician in person. He highlights that this local access allows patients receiving treatment for conditions like Crohn’s disease to engage directly with their pharmacist rather than relying solely on remote services.
The piece presents in-person availability and counseling at a community specialty pharmacy as a valued component of care for patients who must travel for specialty therapeutics.
The author states plainly that, despite the benefits to patients, dispensing some specialty medicines can result in substantial financial strain on the pharmacy. He writes that he sometimes sells medications to patients “at a staggering loss to the pharmacy.” The article links to prior reporting discussing pharmacy losses but does not include numerical figures, detailed accounting, or the specific reimbursement dynamics causing the losses within the excerpt provided.
No quantitative data on the frequency of such losses, the magnitude in dollars, or the proportion of products affected is included in the available text. The author’s statement is presented as a professional observation grounded in his operational experience.
The article’s title and opening lines assert that federal policy does not adequately differentiate between distinct clinical indications for drugs that carry an orphan designation. The author opens with a rhetorical contrast—“Crohn’s disease is most definitely not juvenile idiopathic arthritis”—to underline the clinical differences between conditions that might both be treated with the same therapeutic agent when that agent has multiple approvals or uses.
Although the narrative identifies a tension between clinical nuance and existing policy treatment, the provided content does not specify which statutory provisions, regulatory interpretations, or program rules (for example, those administered by the Health Resources and Services Administration or other agencies) are producing the mismatch. The title references 340B, implying concerns about how the 340B program treats orphan-designated drugs with multiple uses, but the body text supplied does not detail the legal or regulatory mechanisms at issue.
The excerpt supplied contains first-person observations and a clear argument that law and policy should better recognize the differing clinical contexts in which the same drug may be used. However, the source text as provided does not include several elements readers might expect in a policy-focused opinion piece:
Because these details are not reported in the provided source text, they cannot be restated or expanded on here without introducing information not present in the original article.
From the material presented, the key takeaways are: the author operates a rural specialty pharmacy where patients value in-person access to medications like Rinvoq for conditions such as Crohn’s disease; dispensing certain specialty products can create significant financial shortfalls for his pharmacy; and current federal policy—particularly as it relates to orphan-designated drugs and the 340B program—does not, in the author’s view, reflect the clinical differences among indications for the same drug.
The piece calls for legal and policy updates so that the law “catches up” with the clinical reality of drugs that have multiple uses and orphan designations. Specific remedies, data, and regulatory citations were not included in the excerpt provided, so readers seeking those details will need to consult the full article or additional primary sources for comprehensive policy analysis.